Biomedical science is always advancing. The BIA enables new and emerging areas of biomedical science which will change the way R&D is conducted and deliver the life-saving treatments of the future. These strategic technologies also support the UK economy by creating jobs and promoting the UK as a driver for innovation internationally.
As these new technologies disrupt existing research and medical practice, it is important that we have efficient regulatory systems in place. These must protect the rights and safety of citizens and patients, whilst also allowing science to progress at speed.
The BIA is currently focussed on the following strategic technologies:
- Engineering biology (also known as synthetic biology)
- Cell and gene therapy (often referred to as regenerative medicine)
- Personalised medicine
- Antimicrobial resistance
The Engineering Biology Advisory Committee (EBAC), Cell and Gene Therapy Advisory Committee (CGTAC), and Science and Innovation Advisory Committee (SIAC) lead the BIA’s policy development in these technologies, using the expertise and experience of the membership.
Antimicrobial resistance infographic from BIA's Celebrating UK Bioscience report.